Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab in Saphenous Vein Graft Atherosclerosis (ASAP-SVG)
NCT03542110Phase 4Terminated
- Sponsor
- Minneapolis Heart Institute Foundation
- Start
- Aug 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in saphenous vein graft atherosclerosis comparing Alirocumab Arm with Placebo Arm (2 arms). Primary endpoint: Nominal change in intermediate SVG lesion percent atheroma volume at 78 weeks. Started Aug 2018; status: terminated.
02
Drugs
alirocumab
03
Conditions
saphenous vein graft atherosclerosis
Beyond the preview
Go deeper on NCT03542110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03542110.